T Schnitzer

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi Efficacy of tramadol in treatment of chronic low back pain
    T J Schnitzer
    Office of Clinical Research and Training, Northwestern University, Chicago, IL 60611, USA
    J Rheumatol 27:772-8. 2000
  2. ncbi The new analgesic combination tramadol/acetaminophen
    T Schnitzer
    Department of Medicine, Office of Clinical Research and Training, Northwestern University Medical School, Chicago, IL 60611, USA
    Eur J Anaesthesiol Suppl 28:13-7. 2003
  3. ncbi COX-2-selective inhibitors in the treatment of arthritis
    Thomas J Schnitzer
    Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago, IL 60611, USA
    Cleve Clin J Med 69:SI20-30. 2002
  4. ncbi Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee
    Thomas J Schnitzer
    Northwestern Center for Clinical Research, Chicago, Illinois 60611, USA
    Arthritis Rheum 53:827-37. 2005
  5. ncbi Update on alendronate for osteoporosis: once-weekly dosing
    T J Schnitzer
    Northwestern University, Clinical Research and Training, Chicago, Illinois 60611, USA
    Expert Opin Pharmacother 2:1461-72. 2001
  6. ncbi Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors
    T J Schnitzer
    Office of Clinical Research and Training, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Clin Ther 23:313-326; discussion 311-2. 2001
  7. pmc Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
    L Moreland
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Arthritis Res 3:247-52. 2001
  8. ncbi Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies
    Thomas J Schnitzer
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Curr Med Res Opin 21:151-61. 2005
  9. ncbi Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial
    Kenneth D Brandt
    Indiana University School of Medicine, Rheumatology Division, Indianapolis, IN 46202 5100, USA
    Arthritis Rheum 52:2015-25. 2005
  10. ncbi Severity of joint pain and Kellgren-Lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis
    Steven A Mazzuca
    Department of Medicine, Indiana University School of Medicine IUSM, Indianapolis, 46202, USA
    J Rheumatol 32:1540-6. 2005

Detail Information

Publications29

  1. ncbi Efficacy of tramadol in treatment of chronic low back pain
    T J Schnitzer
    Office of Clinical Research and Training, Northwestern University, Chicago, IL 60611, USA
    J Rheumatol 27:772-8. 2000
    ..To evaluate the efficacy and safety of tramadol in the treatment of chronic low back pain...
  2. ncbi The new analgesic combination tramadol/acetaminophen
    T Schnitzer
    Department of Medicine, Office of Clinical Research and Training, Northwestern University Medical School, Chicago, IL 60611, USA
    Eur J Anaesthesiol Suppl 28:13-7. 2003
    ..This article discusses the rationale, efficacy and safety for a novel analgesic combination: tramadol and acetaminophen (paracetamol)...
  3. ncbi COX-2-selective inhibitors in the treatment of arthritis
    Thomas J Schnitzer
    Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago, IL 60611, USA
    Cleve Clin J Med 69:SI20-30. 2002
    ..The use of coxibs to treat OA and RA is recommended as first-line therapy when symptoms of pain and inflammation are present in patients vulnerable to potential NSAID-associated GI toxicity...
  4. ncbi Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee
    Thomas J Schnitzer
    Northwestern Center for Clinical Research, Chicago, Illinois 60611, USA
    Arthritis Rheum 53:827-37. 2005
    ....
  5. ncbi Update on alendronate for osteoporosis: once-weekly dosing
    T J Schnitzer
    Northwestern University, Clinical Research and Training, Chicago, Illinois 60611, USA
    Expert Opin Pharmacother 2:1461-72. 2001
    ..Sales data several months after introduction of once-weekly alendronate into the marketplace demonstrate rapid and extensive acceptance of this new regimen...
  6. ncbi Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors
    T J Schnitzer
    Office of Clinical Research and Training, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Clin Ther 23:313-326; discussion 311-2. 2001
    ..The most recent OA guidelines from the American College of Rheumatology were published in 2000 because new therapies such as the COX-2-selective inhibitors had been introduced for the management of OA...
  7. pmc Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
    L Moreland
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Arthritis Res 3:247-52. 2001
    ..The only adverse event clearly associated with rhIL-11 administration was reaction at the injection site...
  8. ncbi Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies
    Thomas J Schnitzer
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Curr Med Res Opin 21:151-61. 2005
    ....
  9. ncbi Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial
    Kenneth D Brandt
    Indiana University School of Medicine, Rheumatology Division, Indianapolis, IN 46202 5100, USA
    Arthritis Rheum 52:2015-25. 2005
    ..To confirm preclinical data suggesting that doxycycline can slow the progression of osteoarthritis (OA). The primary outcome measure was joint space narrowing (JSN) in the medial tibiofemoral compartment...
  10. ncbi Severity of joint pain and Kellgren-Lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis
    Steven A Mazzuca
    Department of Medicine, Indiana University School of Medicine IUSM, Indianapolis, 46202, USA
    J Rheumatol 32:1540-6. 2005
    ....
  11. ncbi Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies
    Thomas J Schnitzer
    Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Rheumatol 32:1093-105. 2005
    ..5 mg (n=259), or rofecoxib 25 mg (n=527) in a double blind trial [Vioxx, Acetaminophen, Celecoxib Trial (VACT2)]. Results were also pooled with the similarly designed VACT1 trial...
  12. ncbi Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis
    Chin Lee
    Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Arthritis Rheum 53:510-8. 2005
    ..To evaluate the role of common internal controls in a meta-analysis of the relative efficacy of cyclooxygenase 2-selective inhibitors (coxibs) in the treatment of osteoarthritis (OA)...
  13. ncbi Response to expression of concern regarding VIGOR study
    Claire Bombardier
    N Engl J Med 354:1196-9. 2006
  14. ncbi Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
    Daniel O Clegg
    Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    N Engl J Med 354:795-808. 2006
    ..The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis...
  15. ncbi Pain management today - optimising the benefit/risk ratio: defining the role of weak opioids and combination analgesics
    Thomas J Schnitzer
    Clin Rheumatol 25:S1. 2006
  16. ncbi Update on guidelines for the treatment of chronic musculoskeletal pain
    Thomas J Schnitzer
    Department of Medicine, Northwestern University Feinberg School of Medicine, 710 North Lake Shore, 10th Floor, Chicago, IL 60611, USA
    Clin Rheumatol 25:S22-9. 2006
    ....
  17. ncbi Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug
    Steven A Mazzuca
    Indiana University School of Medicine, Indianapolis, 46202 5100, USA
    Arthritis Rheum 51:933-40. 2004
    ..To describe the methods by which remarkable levels of subject retention and adherence were achieved in a 30-month multicenter randomized placebo-controlled trial (RCT) of a disease-modifying osteoarthritis drug (DMOAD)...
  18. ncbi A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis
    Chin Lee
    Northwestern University, The Feinberg School of Medicine, Chicago, Illinois, USA
    Arthritis Rheum 51:746-54. 2004
    ....
  19. ncbi Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial
    Gregory P Geba
    Merck and Co Inc, US Human Health, PO Box 4, West Point, PA 19486 0004, USA
    JAMA 287:64-71. 2002
    ..Osteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2)...
  20. ncbi Update of ACR guidelines for osteoarthritis: role of the coxibs
    Thomas J Schnitzer
    Office of Clinical Research and Training, Northwestern University Medical School, Evanston, IL 60611, USA
    J Pain Symptom Manage 23:S24-30; discussion S31-4. 2002
    ..It is anticipated that the guidelines for the management of OA will continue to evolve as new therapies become available...
  21. ncbi Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use
    Loren Laine
    University of Southern California School of Medicine, Los Angeles 90033, USA
    Gastroenterology 124:288-92. 2003
    ..We performed a post hoc analysis of serious lower GI clinical events with a nonselective NSAID and a COX-2-selective agent in a prospective, double-blind, randomized GI outcomes trial...
  22. ncbi Means, responders, and meaning: evaluation of clinical trials in osteoarthritis
    Thomas J Schnitzer
    Arthritis Rheum 48:3001-3. 2003
  23. ncbi An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis
    Thomas J Schnitzer
    Northwestern Center for Clinical Research, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Clin Ther 25:3162-72. 2003
    ..This study assessed prescribing patterns for rofecoxib and celecoxib in the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as differences in prescribing patterns across physician specialties...
  24. ncbi Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
    Thomas J Schnitzer
    Office of Clinical Research and Training, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Lancet 364:665-74. 2004
    ....
  25. ncbi Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
    Michael E Farkouh
    Cardiovascular Clinical Research Center, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
    Lancet 364:675-84. 2004
    ....
  26. ncbi Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial
    Thomas J Schnitzer
    Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Arthritis Rheum 51:549-57. 2004
    ..To compare the efficacy and tolerability of the novel cyclooxygenase 2-selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA)...
  27. ncbi Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies
    Steven S Smugar
    Merck and Co, Inc, West Point, PA 19486 0004, USA
    Curr Med Res Opin 22:1353-67. 2006
    ..To compare the efficacy of rofecoxib and celecoxib for the treatment of knee or hip OA over 6 weeks...
  28. ncbi A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain
    Thomas J Schnitzer
    Office of Clinical Research and Training, Northwestern University, Chicago, Illinois, USA
    J Pain Symptom Manage 28:72-95. 2004
    ..More rigorously designed trials should be implemented to establish comparative efficacy and safety of drugs used to treat chronic and acute LBP...
  29. ncbi Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial
    Susan L Greenspan
    University of Pittsburgh Osteoporosis Prevention and Treatment Center, 1110 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA
    Ann Intern Med 136:742-6. 2002
    ..Many elderly female residents of long-term care facilities have osteoporosis and could benefit from intervention to increase bone density...